Stock Track | GlaxoSmithKline Soars 5.02% in Pre-market on Strong Q4 Earnings Beat and Upbeat 2026 Outlook

Stock Track

Feb 04

GlaxoSmithKline PLC (GSK) shares soared 5.02% in pre-market trading on Wednesday, following the release of its fourth-quarter financial results that exceeded market expectations.

The pharmaceutical giant reported core earnings of £0.26 per share for Q4, beating the FactSet consensus estimate of £0.24, with sales reaching £8.62 billion, also above the expected £8.47 billion. For 2026, the company issued a growth outlook projecting core EPS to increase 7% to 9% and sales to rise 3% to 5%, reinforcing investor confidence in its future performance.

Additional positive catalysts included a 12.5% increase in the quarterly dividend and a maintained Buy rating from Jefferies with a £21.00 price target. The strong results were driven by double-digit growth in GSK's specialty medicines portfolio, particularly in HIV treatments, oncology, and immunology drugs, highlighting the company's robust operational execution and financial health.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1122472604"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1122472604\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1122472604?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-04 19:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1122472604","market":"us","top_or_hot":-1,"title":"Stock Track | GlaxoSmithKline Soars 5.02% in Pre-market on Strong Q4 Earnings Beat and Upbeat 2026 Outlook","media":"Stock Track","content":"<p>GlaxoSmithKline PLC (GSK) shares soared 5.02% in pre-market trading on Wednesday, following the release of its fourth-quarter financial results that exceeded market expectations.</p><p>The pharmaceutical giant reported core earnings of £0.26 per share for Q4, beating the FactSet consensus estimate of £0.24, with sales reaching £8.62 billion, also above the expected £8.47 billion. For 2026, the company issued a growth outlook projecting core EPS to increase 7% to 9% and sales to rise 3% to 5%, reinforcing investor confidence in its future performance.</p><p>Additional positive catalysts included a 12.5% increase in the quarterly dividend and a maintained Buy rating from Jefferies with a £21.00 price target. The strong results were driven by double-digit growth in GSK's specialty medicines portfolio, particularly in HIV treatments, oncology, and immunology drugs, highlighting the company's robust operational execution and financial health.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | GlaxoSmithKline Soars 5.02% in Pre-market on Strong Q4 Earnings Beat and Upbeat 2026 Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | GlaxoSmithKline Soars 5.02% in Pre-market on Strong Q4 Earnings Beat and Upbeat 2026 Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-04 19:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>GlaxoSmithKline PLC (GSK) shares soared 5.02% in pre-market trading on Wednesday, following the release of its fourth-quarter financial results that exceeded market expectations.</p><p>The pharmaceutical giant reported core earnings of £0.26 per share for Q4, beating the FactSet consensus estimate of £0.24, with sales reaching £8.62 billion, also above the expected £8.47 billion. For 2026, the company issued a growth outlook projecting core EPS to increase 7% to 9% and sales to rise 3% to 5%, reinforcing investor confidence in its future performance.</p><p>Additional positive catalysts included a 12.5% increase in the quarterly dividend and a maintained Buy rating from Jefferies with a £21.00 price target. The strong results were driven by double-digit growth in GSK's specialty medicines portfolio, particularly in HIV treatments, oncology, and immunology drugs, highlighting the company's robust operational execution and financial health.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GSK","symbol_name":"葛兰素史克","start_time":0,"source_url":"","article_id":"1122472604","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1122472604","pubTimestamp":1770204889,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"GlaxoSmithKline PLC (GSK) shares soared 5.02% in pre-market trading on Wednesday, following the release of its fourth-quarter financial results that exceeded market expectations.The pharmaceutical...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GSK":"葛兰素史克"},"translate_title":"个股追踪|葛兰素史克盘前飙升5.02%，第四季度盈利强劲，2026年前景乐观","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GSK":1},"content_text":"GlaxoSmithKline PLC (GSK) shares soared 5.02% in pre-market trading on Wednesday, following the release of its fourth-quarter financial results that exceeded market expectations.The pharmaceutical giant reported core earnings of £0.26 per share for Q4, beating the FactSet consensus estimate of £0.24, with sales reaching £8.62 billion, also above the expected £8.47 billion. For 2026, the company issued a growth outlook projecting core EPS to increase 7% to 9% and sales to rise 3% to 5%, reinforcing investor confidence in its future performance.Additional positive catalysts included a 12.5% increase in the quarterly dividend and a maintained Buy rating from Jefferies with a £21.00 price target. The strong results were driven by double-digit growth in GSK's specialty medicines portfolio, particularly in HIV treatments, oncology, and immunology drugs, highlighting the company's robust operational execution and financial health.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}